UNSPSC 51322603: Tazasubrate

This classification denotes an anti-lipidemic agent with the molecular formula C18H17NO3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6SGF1AP698, chemically known as benzeneacetic acid, alpha-(((6-ethoxy-2-benzothiazolyl)thio)methyl)-, (+-)- but generally known as tazasubrate, which bears US NIH Compound Identifier 174749. European Medicines Agency schedules Tazasubrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10845MIG.

UNSPSC 51322603 Tazasubrate is a Commodity code covering pharmaceutical products—specifically, medications and drugs supplied to state and local health agencies, fire rescue services, and health benefit programs. Recent state and local solicitations under this code reflect procurement of specific drug formulations for emergency medical services, pharmacy benefit programs, and multi-state cooperative purchasing arrangements. The City of Tampa's sealed bid for Advanced Life Support Medications (Bid No. 26-P-00188) exemplifies direct procurement of named pharmaceutical products—Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials—for use by Tampa Fire Rescue, with firm pricing, nine-month minimum shelf life, and 365-day warranty requirements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and over-the-counter products demonstrates larger-scale state and local procurement through cooperative vehicles serving multiple jurisdictions. Issuing bodies include city purchasing departments (Tampa), state health agencies (Texas Health and Human Services Commission), and state administration offices administering cooperative purchasing (Minnesota Department of Administration). Fire rescue services and state health benefit programs are primary end-users.

Geographic activity centers on Florida, Texas, and Minnesota, with multi-state reach through MMCAP's cooperative vehicle serving Oregon and other participating jurisdictions. Representative recent opportunities include the City of Tampa's IFB for Advanced Life Support Medications (response due April 8, 2026, estimated contract value $40,000.00) and MMCAP's RFP for Generic Multi Source Pharmaceuticals and OTC Products (due March 26, 2026, effective July 1, 2026), both requiring vendors to supply through authorized wholesalers or direct fulfillment with NDC-specific product specifications, cGMP and DSCSA compliance, and pricing submitted in multiple formats (flat price, net price, or WAC-minus). The Texas Health and Human Services Commission's RFI on Direct-to-Manufacturer Prescriptions (posted March 27, 2026) signals emerging state interest in direct contracting models outside traditional PBM and GPO channels. Procurement emphasizes product availability dates, expiration-date requirements, supply-chain security, and multi-year contract terms with optional renewal or extension provisions.